Turgay BULUT, Mehmet Ali EKİCİ, Bülent TUCER, Seyit Kaan BAŞARSLAN

The effect of chloroquine treatment in malignant astrocytomas on prognosis

To investigate the adjuvant role of the antimutagenic agent chloroquine in the treatment of patients with malignant astrocytomas (MAs). Materials and methods: Clinical research was conducted at the Neurosurgery Clinic of the Erciyes University School of Medicine, from September 2003 to April 2007, on 37 patients diagnosed with MA after tumor resection subsequent to craniotomy. Chloroquine treatment was started on a daily dose of 150 mg, additional to the patients' radiotherapy and chemotherapy protocol, and was continued throughout the 43-month surveillance period. A control group was formed of 81 patients with MA after the craniotomy. Results: While the mean survival time of the patients who were treated with chloroquine was found to be 15 months, during the observation period 7 of these patients (18.9%) were alive throughout. In the control group, 20 patients (35.1%) were alive throughout the observation period and their mean survival time was 17 months. There were no statistical differences between the control and chloroquine groups (P > 0.05). Conclusion: The chloroquine treatment was not been found to be effective for the medical treatment of MAs.

Anahtar Kelimeler:

Key words: Chloroquine treatment, malignant astrocytomas, prognosis, antimutagenic effect

The effect of chloroquine treatment in malignant astrocytomas on prognosis

Keywords:

Key words: Chloroquine treatment, malignant astrocytomas, prognosis, antimutagenic effect,

PDF

___

Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol 2004; 31: 635–44.
Kim EL, Wüstenberg R, Rübsam A, Schmitz-Salue C, Warnecke G, Bücker EM et al. Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol 2010; 12: 389–400.
Kokunai T, Tamaki N, Matsumoto S. ACNU-resistant mutants of 9L rat glioma cell line. Isolation and preliminary characterization of these subclones. J Neurosurg 1985; 63: 583–
Cohen A, Modan M. Some epidemiologic aspects of neoplastic disease in Israeli immigrant population III. Brain tumors. Cancer 1968; 22: 1323–8.
Sotelo J, Briceño E, López-González MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006; 144: 337–43.
Kleihues P, Cavenee WK, editors. Pathology and Genetics of Tumors of the Nervous System. Lyon: IARC Press; 2000.
Sawaya R, Hammound M, Schoppa D, Hess KR, Shi WM, Wildrick DM. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998; 42: 1044–56.
Bach MK Reduction in the frequency of mutation to resistance to cytarabine in L1210 murine leukemic cells by treatment with quinacrine hydrochloride. Cancer Res 1969; 29: 1881–5.
Hoffman GR, Deschenes SM, Manyin T, Fuchs RP. Mutagenicity of acridines in a reversion assay based on tetracycline resistance in plasmid pBR322 in Escherichia coli. Mutat Res 1996; 351: 33–
Spriggs DR, Sherman ML, Imamura K, Mohri M, Rodriguez C, Robbins G et al. Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor. Cancer Res 1990; 50: 7101–7.
Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350–4.
Pfab R, Schachtschabel DO, Kern HF. Ultrastructural studies of the effect of x-rays and quinacrine (Atebrin) or chloroquine (Resochin) — alone or in combination — on Harding-Passey melanoma cells in monolayer culture. Strahlentherapie 1985; 161: 711–8.
Jensen PB, Sİrensen BS, Sehested M, Grue P, Demant EJ, Hansen HH. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res 1994; 54: 2959–63.
Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J Immunol 2000; 165: 1534–
Hofmann J. Modulation of protein kinase C in antitumor treatment. Rev Physiol Biochem Pharmacol 2001; 142: 1–96.
Reyes S, Herrera LA, Ostrosky P, Sotelo J. Quinacrine enhances carmustine therapy of experimental rat glioma. Neurosurgery 2001; 49: 969–73.
Briceno E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus 2003; 14: 2–3.
Briceno E, Calderon A, Sotelo J. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol 2007; 67: 388–91.
Kumabe F, Kamaya T, Yoshimoto, Miozi K. Follow-up study of malignant astrocytomas showing complete response after initial treatment. No Shinkei Geka 1994; 22: 545–51 (in Japanese).
Murovic J, Turowski K, Wilson CB, Hoshino T, Levin V. Computerized tomography in the prognosis of malignant cerebral gliomas. J Neurosurg 1986; 65: 790–806.
Mahaley MS, Mettlin C, Natarajan N, Laws ER Jr, Peace BB. National survey of patterns of care for brain-tumor patients. J Neurosurg 1989; 71: 826–36.
Barker FG 2nd, Chang M, Larson DA, Sneed PK, Wara WM, Wilson CB et al. Age and radiation response in glioblastoma multiforme. Neurosurgery 2001; 45: 1288–98.
Curran WJ, Scott CB, Weinstein AS, Martin LA, Nelson JS, Phillips TL et al. Survival comparison of radiosurgeryeligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J Clin Oncol. 1993; 11: 857–62.
Barker FG 2nd, Chang SM, Valk PE, Pounds TR, Prados MD. 18-Fluorodeoxyglucose uptake and a survival of patients with suspected recurrent malignant glioma. Cancer 1997; 79: 115–
Salvati M, Pichierri A, Piccirilli M, Floriana Brunetto GM, D’Elia A, Artizzu S et al. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients. J Neurosurg. 2012; 117: 204–11.
Salcman M, Broadwell RD. The blood-brain barrier. In: Salcman M, editor. Neurobiology of Brain Tumors, Vol. 4. Baltimore: Williams & Wilkins; 1991. p. 229–49.
Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, Nimsky C. Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro Oncol 2011; 13: 1339–48.
Bentzen SM, Thames HD. Tumor volume and local control probability: clinical data and radiobiological interpretations. Int J Radiat Oncal Bio Phys 1996; 36: 247–51.
Salcman M. Surgical decision-making for malignant brain tumors. Clin Neurosurg 1989; 35: 285–313.
Iliadis G, Kotoula V, Chatzisotiriou A, Televantou D, Eleftheraki AG, Lambaki S et al. Volumetric and MGMT parameters in glioblastoma patients: survival analysis. BMC Cancer 2012; 12: